The National Agency for Food and Drug Administration and Control (NAFDAC) has issued a warning to health workers and the public following a nationwide recall of products linked to EUROPHARM Laboratories in Jos.
In a message posted on its X account on Friday, the agency explained that it commenced enforcement operations against Europharm Laboratories, Eurolink Nigeria Ltd., located at Plot Pl., 7354, Anglo Jos, New Industrial Area, after receiving credible intelligence and carrying out regulatory checks.
NAFDAC said its findings showed that the company had been manufacturing, selling, and distributing a range of pharmaceutical and other controlled products without obtaining the required marketing authorisation (MA).
During the inspection, officials uncovered several products at the site, many of which were either being produced or supplied in violation of NAFDAC’s regulatory requirements.
The agency added that laboratory testing conducted on some of the items revealed alarming quality deficiencies, raising serious concerns for public health.
According to NAFDAC, test results showed very low levels of Active Pharmaceutical Ingredients (API) in Linmoxyn (Amoxicillin) suspension and Linmoxyn (Amoxicillin 500mg capsules). The findings were as follows:
Linmoxyn (Amoxicillin suspension) failed analysis with API levels of 13.9% and 18.4%, far below the approved standard. Linmoxyn (Amoxicillin 500mg capsules) also failed, recording only 48.3% API content, confirming it to be highly substandard.
NAFDAC further stated that several other products carrying NAFDAC Registration Numbers (NRNs) were found at the Europharm facility.
The agency warned that medicines containing low API levels pose multiple dangers, including treatment failure, antimicrobial resistance, and other potential risks to users.
The products listed in the mop-up include Linocloxin (Ampicillin 125mg & Cloxacillin 125mg) powder for oral suspension 100ml, Linromycine (Erythromycin) powder for suspension 100ml, Linocillin (Ampicillin) powder for oral suspension 50ml, and Linmoxyn (Amoxicillin 125mg) suspension 60ml.
Others include Eurogyl (Metronidazole suspension) 50ml, Naflin (Cough Expectorant) 100ml, Natacid (Magnesium Trisilicate suspension) 100ml, Navit-B Syrup (Vitamin B Complex) 100ml, Fountain B-12 (Blood Tonic) 100ml and 200ml.
Also affected are Vitamin-C Syrup 100ml, Eurogyl (Metronidazole) Tablet blister 10×10 tabs, Eurogyl (Metronidazole) x1000 tablets, Euramol (Paracetamol) x1000 tablets, Euramox (Mebendazole 100mg) tablets, Linotrim (Cotrimoxazole suspension) 50ml, and Linoquine (Chloroquine Phosphate syrup 80mg/5ml) 60ml.
NAFDAC stated that all zonal directors and state coordinators have been instructed to conduct surveillance and remove all substandard products from circulation in their respective regions.
The agency urged distributors, sellers, health professionals, and caregivers to remain alert within the supply chain to prevent the sale, distribution, or use of unsafe medicines.
It also encouraged healthcare workers and members of the public to report any suspected cases of substandard or falsified medicines or medical devices to the nearest NAFDAC office.
